Your AI-Trained Oncology Knowledge Connection!
Expert hematologist/oncologists review key datasets in leukemia presented at the ASH 2022 Annual Meeting.
Supported in part by Amgen Oncology, Servier, and Takeda Oncology. Content developed independently by OncLive®.
EP. 1: ASH 2022: Updates in the Acute Lymphocytic Leukemia Treatment Landscape
Following the ASH 2022 Annual Meeting, hematologic oncology experts discuss updated data in acute lymphocytic leukemia.
EP. 2: ASH 2022: Recent Advances in Chronic Myeloid Leukemia
Experts in hematologic oncology review and analyze updated data in chronic myeloid leukemia from ASH 2022.
EP. 3: Acute Myeloid Leukemia: Updates From The ASH 2022 Annual Meeting
Shared insight on recently updated data in acute myeloid leukemia following the ASH 2022 annual meeting.
First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer
Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer